May 29 – June 2, 2026 | Chicago, IL
Date: May 29 – June 2, 2026
Exhibit location:
McCormick Place | Chicago
Hall A, South Building
Booth:
27017
Saturday, May 30: 9:00 – 17:00 CDT
Sunday, May 31: 9:00 – 17:00 CDT
Monday, June 1: 9:00 – 17:00 CDT
| Date/Time | Title | Abstract # ▲ ▼ | Type ▲ ▼ | Category | Author ▲ ▼ | Location |
|---|---|---|---|---|---|---|
|
- |
Exploratory biomarker analysis of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with PD-L1-positive non-small cell lung cancer (NSCLC) in AdvanTIG-105 |
— | — | Tislelizumab | Jun Zhang, MD, PhD | — |
|
- |
A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: First disclosure of clinical data |
— | — | Early Clinical | Hong Jae Chon, MD, PhD | — |
|
- |
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion |
— | — | Early Clinical | Binghe Xu, MD, PhD | — |
|
- |
RATIONALE-315: Post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy |
— | — | Tislelizumab | Gustavo Schvartsman, MD, PhD | — |
|
- |
Quality-adjusted survival comparison for tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with peritoneal metastasis (PM): Long-term follow-up from RATIONALE-305 |
— | — | Tislelizumab | Rutika Mehta, MD, MPH | — |
|
- |
First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer (BC): A phase 1 safety expansion |
— | — | Early Clinical | Shom Goel, MBBS, PhD | — |
|
- |
A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors |
— | — | Early Clinical | Judith Raimbourg, MD | — |
|
- |
Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4 – targeting ADC) from pharmacokinetics, efficacy and safety perspectives |
— | — | Early Clinical | Hugh Giovinazzo, PharmD, PhD | — |
|
- |
First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) achieves undetectable minimal residual disease (uMRD) rates of >90%, including in patients with del(17p)/TP53 |
— | — | Sonrotoclax, Zanubrutinib | Constantine S. Tam, MBBS, MD | — |
|
- |
Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2) |
— | — | Sonrotoclax, Zanubrutinib | Mazyar Shadman, MD, MPH | — |
|
- |
Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA |
— | — | Zanubrutinib | Constantine S. Tam, MBBS, MD | — |
|
- |
Navigating the post–covalent Bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma (MCL): Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization (HCRU) |
— | — | HEOR/RWE | Alvaro Alencar, MD | — |
|
- |
Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) |
— | — | HEOR/RWE | Daniel A. Ermann, MD | — |
|
- |
Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL) |
— | — | HEOR/RWE | Michael Fradley, MD | — |
|
- |
Real-world treatment survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the United States |
— | — | HEOR/RWE | Ryan Jacobs, MD | — |
|
- |
A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States |
— | — | HEOR/RWE | Yucai Wang , MD, PhD | — |
|
- |
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01 |
— | — | Tislelizumab | Sun Young Rha, MD, PhD | — |
|
- |
Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01 |
— | — | Tislelizumab | Elena Elimova, MD | — |
